"I have stock in Target and they're a local company," she said, adding that the Minnesota-based company was "so great" before it decided at the end of January to scale back its DEI programs ...

Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ...

Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell ...